O1-056 - The Effectiveness of Upfront Auto PBSCT for the Treatment of Young 14 Cases of PCNSL

Abstract

ABSTRACT Method Fourteen cases of young (under 66 years old) PCNSL who were treated at Anjo-Kosei Hospital between May 2002 and December 2011 enrolled in this study. Result Among 14 cases, 35–65 (median 56) years old, the pathorogical diagnosis are: 13 cases of diffuse large B cell lymphoma (DLBCL), 1 case of intravascular large B cell lymphoma (IVL), and 6 cases are treated by upfront auto PBSCT. The median follow-up was 38.7 months. Between auto-PBSCT and no-auto-PBSCT arms, there are no significant differences in the patient's background such as age (53.5 years old versus 58 years old), performance status, serum LDH (205 versus 198), serum sIL2R (436 versus 680). We checked the prognostic scoring system for PCNSL, but there are no differences between the two arms. In auto-PBSCT arm, they were treated by high-dose MTX-based therapy and high-dose AraC therapy, when they achieved CR/ near CR, they were carried out auto PBSCH. The conditioning regimen for auto PBSCT was LEED therapy in all cases. The overall survival at 4 years was superior in the auto-PBSCT arm (75.0% versus 41.7% P = 0.262). The relapse rate at 4 years was superior in the auto-PBSCT arm (25.0% versus 61.9% P = 0.273). In auto PBSCT arm, five cases maintain complete remissions and no one has severe complications such as leukoencephalopathy. In no-auto PBSCT arm, four cases are died from the relapse and only three cases maintain complete remission. Conclusion Our results emphasize the effectiveness and safety of upfront auto PBSCT to PCNSL.